227 related articles for article (PubMed ID: 32967102)
41. Deciphering the key mechanisms leading to alteration of lipid metabolism in Drosophila model of Huntington's disease.
Singh A; Agrawal N
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166127. PubMed ID: 33722743
[TBL] [Abstract][Full Text] [Related]
42. Amyloidogenic Oligomerization Transforms Drosophila Orb2 from a Translation Repressor to an Activator.
Khan MR; Li L; Pérez-Sánchez C; Saraf A; Florens L; Slaughter BD; Unruh JR; Si K
Cell; 2015 Dec; 163(6):1468-83. PubMed ID: 26638074
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila.
Steffan JS; Bodai L; Pallos J; Poelman M; McCampbell A; Apostol BL; Kazantsev A; Schmidt E; Zhu YZ; Greenwald M; Kurokawa R; Housman DE; Jackson GR; Marsh JL; Thompson LM
Nature; 2001 Oct; 413(6857):739-43. PubMed ID: 11607033
[TBL] [Abstract][Full Text] [Related]
44. Aging causes distinct characteristics of polyglutamine amyloids in vivo.
Tonoki A; Kuranaga E; Ito N; Nekooki-Machida Y; Tanaka M; Miura M
Genes Cells; 2011 May; 16(5):557-64. PubMed ID: 21466635
[TBL] [Abstract][Full Text] [Related]
45. Morphometric analysis of Huntington's disease neurodegeneration in Drosophila.
Song W; Smith MR; Syed A; Lukacsovich T; Barbaro BA; Purcell J; Bornemann DJ; Burke J; Marsh JL
Methods Mol Biol; 2013; 1017():41-57. PubMed ID: 23719906
[TBL] [Abstract][Full Text] [Related]
46. Lessons from animal models of Huntington's disease.
Rubinsztein DC
Trends Genet; 2002 Apr; 18(4):202-9. PubMed ID: 11932021
[TBL] [Abstract][Full Text] [Related]
47. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.
van Roon-Mom WM; Pepers BA; 't Hoen PA; Verwijmeren CA; den Dunnen JT; Dorsman JC; van Ommen GB
BMC Mol Biol; 2008 Oct; 9():84. PubMed ID: 18844975
[TBL] [Abstract][Full Text] [Related]
48. Huntingtin aggregation and toxicity in Huntington's disease.
Bates G
Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
[TBL] [Abstract][Full Text] [Related]
49. The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington's disease.
Wanker EE; Ast A; Schindler F; Trepte P; Schnoegl S
J Neurochem; 2019 Nov; 151(4):507-519. PubMed ID: 31418858
[TBL] [Abstract][Full Text] [Related]
50. Copy-number variation of the neuronal glucose transporter gene SLC2A3 and age of onset in Huntington's disease.
Vittori A; Breda C; Repici M; Orth M; Roos RA; Outeiro TF; Giorgini F; Hollox EJ;
Hum Mol Genet; 2014 Jun; 23(12):3129-37. PubMed ID: 24452335
[TBL] [Abstract][Full Text] [Related]
51. 3'UTR of mRNA Encoding CPEB Protein Orb2 Plays an Essential Role in Intracellular Transport in Neurons.
Kozlov EN; Deev RV; Tokmatcheva EV; Tvorogova A; Kachaev ZM; Gilmutdinov RA; Zhukova M; Savvateeva-Popova EV; Schedl P; Shidlovskii YV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443751
[TBL] [Abstract][Full Text] [Related]
52. The Tiny
Rosas-Arellano A; Estrada-Mondragón A; Piña R; Mantellero CA; Castro MA
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30110961
[TBL] [Abstract][Full Text] [Related]
53. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
[TBL] [Abstract][Full Text] [Related]
54. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
[TBL] [Abstract][Full Text] [Related]
55. Focusing the pivotal role of nanotechnology in Huntington's disease: an insight into the recent advancements.
Singh S; Hema ; Sharma N; Sachdeva M; Behl T; Zahoor I; Fuloria NK; Sekar M; Fuloria S; Subramaniyan V; Alsubayiel AM; Dailah HG; Naved T; Bhatia S; Al-Harrasi A; Aleya L
Environ Sci Pollut Res Int; 2022 Oct; 29(49):73809-73827. PubMed ID: 36100788
[TBL] [Abstract][Full Text] [Related]
56. Orb2 enables rare-codon-enriched mRNA expression during Drosophila neuron differentiation.
Stewart RK; Nguyen P; Laederach A; Volkan PC; Sawyer JK; Fox DT
Nat Commun; 2024 Jun; 15(1):5270. PubMed ID: 38902233
[TBL] [Abstract][Full Text] [Related]
57. Fibrillogenesis of huntingtin and other glutamine containing proteins.
Lyubchenko YL; Krasnoslobodtsev AV; Luca S
Subcell Biochem; 2012; 65():225-51. PubMed ID: 23225006
[TBL] [Abstract][Full Text] [Related]
58. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
[TBL] [Abstract][Full Text] [Related]
59. Pathogenic SREK1 decrease in Huntington's disease lowers TAF1 mimicking X-linked dystonia parkinsonism.
Hernández IH; Cabrera JR; Santos-Galindo M; Sánchez-Martín M; Domínguez V; García-Escudero R; Pérez-Álvarez MJ; Pintado B; Lucas JJ
Brain; 2020 Jul; 143(7):2207-2219. PubMed ID: 32533168
[TBL] [Abstract][Full Text] [Related]
60. Nucleic Acid Therapeutics in Huntington's Disease.
Singh K; Roy I
Recent Pat Biotechnol; 2019; 13(3):187-206. PubMed ID: 30747088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
